6533b82ffe1ef96bd1295119
RESEARCH PRODUCT
Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC)
Yann BouvetJan HoflackJean-bernard DeloyeAlexandre CochetNicolas IsambertPhilippe GennePetra BlomCharles CoutantAurélie BertautCyril BerthetPascal FoucherGilles ViotJean-marc VrigneaudBruno CoudertPierre Fumoleausubject
Cancer Research[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingnon-small cell lung cancer (NSCLC)[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicinemedicineIn patientComputingMilieux_MISCELLANEOUSmedicine.diagnostic_testbusiness.industryPet imagingmedicine.diseaseEGFR Tyrosine Kinase Inhibitorsrespiratory tract diseases3. Good health[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingOncologyEgfr mutationPositron emission tomography030220 oncology & carcinogenesisMutation (genetic algorithm)Cancer researchbusiness030215 immunologydescription
e24184Background: Multiple EGFR tyrosine kinase inhibitors (TKIs) are approved for treatment of NSCLC harboring EGFR activating mutations or secondary TKIs resistant mutation. We evaluate a new PET...
year | journal | country | edition | language |
---|---|---|---|---|
2018-10-13 |